Cargando…
The use of antimetabolites as adjunctive therapy in the surgical treatment of pterygium
BACKGROUND: Pterygium is a proliferative disease with hyperplastic growth of corneoconjunctival fibro vascular tissue onto the cornea. Surgical therapy can be used to successfully manage pterygia; however, recurrence remains a problem. To reduce recurrence, surgical management may include autoconjun...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3497463/ https://www.ncbi.nlm.nih.gov/pubmed/23152665 http://dx.doi.org/10.2147/OPTH.S38388 |
_version_ | 1782249748431896576 |
---|---|
author | Kareem, Alyaà Abood Farhood, Qasim Kadhim Alhammami, Hussein Ali |
author_facet | Kareem, Alyaà Abood Farhood, Qasim Kadhim Alhammami, Hussein Ali |
author_sort | Kareem, Alyaà Abood |
collection | PubMed |
description | BACKGROUND: Pterygium is a proliferative disease with hyperplastic growth of corneoconjunctival fibro vascular tissue onto the cornea. Surgical therapy can be used to successfully manage pterygia; however, recurrence remains a problem. To reduce recurrence, surgical management may include autoconjunctival grafting, lamellar keratoplasty, amniotic membrane transplantation, and intraoperative antimetabolites application. PURPOSE: To assess the safety and the efficacy of intraoperative mitomycin C (MMC) and 5-fluorouracil (5-FU) application in preventing recurrence of pterygium after excision. PATIENTS AND METHODS: The study design is a prospective, randomized clinical trial. A total of 50 patients with bilateral pterygium were recruited for the study. The first group of patients (25) underwent surgical excision of the pterygium with bare sclera in one eye and MMC was applied as adjunctive therapy for the other eye. In the second group 5-FU was used instead of MMC. Recurrences and postoperative complications were measured in the two groups. The mean follow up period of the patients was 18.8 months. Chi square test, odds ratio, and frequency distribution were used to determine significance levels; P-values <0.05 were considered statistically significant. RESULTS: In group 1 the recurrence rate was 8% for the MMC treated eyes and 32% for their fellow eyes (P = 0.03). In group 2 the rate was 18% for the 5-FU treated eyes and 34% for their fellow eyes (P = 0.07). No serious complications were recorded in either group. CONCLUSION: Both MMC and 5-FU reduce the recurrence rate of pterygium after simple surgical excision; statistically, the effect of the former was significant, but insignificant for the latter. Both antimetabolites were safe during the whole study period, but 5-FU recurrent cases showed cosmetically unacceptable appearances with excessive vascularization. MMC, but not 5-FU, is recommended as an adjunctive therapy to prevent recurrence of pterygium after surgical excision. |
format | Online Article Text |
id | pubmed-3497463 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-34974632012-11-14 The use of antimetabolites as adjunctive therapy in the surgical treatment of pterygium Kareem, Alyaà Abood Farhood, Qasim Kadhim Alhammami, Hussein Ali Clin Ophthalmol Original Research BACKGROUND: Pterygium is a proliferative disease with hyperplastic growth of corneoconjunctival fibro vascular tissue onto the cornea. Surgical therapy can be used to successfully manage pterygia; however, recurrence remains a problem. To reduce recurrence, surgical management may include autoconjunctival grafting, lamellar keratoplasty, amniotic membrane transplantation, and intraoperative antimetabolites application. PURPOSE: To assess the safety and the efficacy of intraoperative mitomycin C (MMC) and 5-fluorouracil (5-FU) application in preventing recurrence of pterygium after excision. PATIENTS AND METHODS: The study design is a prospective, randomized clinical trial. A total of 50 patients with bilateral pterygium were recruited for the study. The first group of patients (25) underwent surgical excision of the pterygium with bare sclera in one eye and MMC was applied as adjunctive therapy for the other eye. In the second group 5-FU was used instead of MMC. Recurrences and postoperative complications were measured in the two groups. The mean follow up period of the patients was 18.8 months. Chi square test, odds ratio, and frequency distribution were used to determine significance levels; P-values <0.05 were considered statistically significant. RESULTS: In group 1 the recurrence rate was 8% for the MMC treated eyes and 32% for their fellow eyes (P = 0.03). In group 2 the rate was 18% for the 5-FU treated eyes and 34% for their fellow eyes (P = 0.07). No serious complications were recorded in either group. CONCLUSION: Both MMC and 5-FU reduce the recurrence rate of pterygium after simple surgical excision; statistically, the effect of the former was significant, but insignificant for the latter. Both antimetabolites were safe during the whole study period, but 5-FU recurrent cases showed cosmetically unacceptable appearances with excessive vascularization. MMC, but not 5-FU, is recommended as an adjunctive therapy to prevent recurrence of pterygium after surgical excision. Dove Medical Press 2012 2012-11-08 /pmc/articles/PMC3497463/ /pubmed/23152665 http://dx.doi.org/10.2147/OPTH.S38388 Text en © 2012 Kareem et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Original Research Kareem, Alyaà Abood Farhood, Qasim Kadhim Alhammami, Hussein Ali The use of antimetabolites as adjunctive therapy in the surgical treatment of pterygium |
title | The use of antimetabolites as adjunctive therapy in the surgical treatment of pterygium |
title_full | The use of antimetabolites as adjunctive therapy in the surgical treatment of pterygium |
title_fullStr | The use of antimetabolites as adjunctive therapy in the surgical treatment of pterygium |
title_full_unstemmed | The use of antimetabolites as adjunctive therapy in the surgical treatment of pterygium |
title_short | The use of antimetabolites as adjunctive therapy in the surgical treatment of pterygium |
title_sort | use of antimetabolites as adjunctive therapy in the surgical treatment of pterygium |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3497463/ https://www.ncbi.nlm.nih.gov/pubmed/23152665 http://dx.doi.org/10.2147/OPTH.S38388 |
work_keys_str_mv | AT kareemalyaaabood theuseofantimetabolitesasadjunctivetherapyinthesurgicaltreatmentofpterygium AT farhoodqasimkadhim theuseofantimetabolitesasadjunctivetherapyinthesurgicaltreatmentofpterygium AT alhammamihusseinali theuseofantimetabolitesasadjunctivetherapyinthesurgicaltreatmentofpterygium AT kareemalyaaabood useofantimetabolitesasadjunctivetherapyinthesurgicaltreatmentofpterygium AT farhoodqasimkadhim useofantimetabolitesasadjunctivetherapyinthesurgicaltreatmentofpterygium AT alhammamihusseinali useofantimetabolitesasadjunctivetherapyinthesurgicaltreatmentofpterygium |